Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060898 | 0.92 | MEN1 (0.46) | MEN1KMT2ACNR2HPGDCNR1 | |
| SCHEMBL19072007 | 0.91 | MEN1 (0.34) | MEN1KMT2ACNR2ALDH1A1HPGD | |
| SCHEMBL16480354 | 0.86 | KDM4E (0.43) | HPGDMAPT | |
| SCHEMBL16480353 | 0.85 | KDM4E (0.31) | CNR2HPGDNPC1MAPT | |
| SCHEMBL19072247 | 0.84 | MEN1 (0.45) | MEN1KMT2ACNR2HPGDCNR1 | |
| SCHEMBL16477955 | 0.82 | — | — | |
| SCHEMBL27837668 | 0.81 | MAPT (0.44) | ALDH1A1HPGDNPC1PDK2MAPT | |
| SCHEMBL16480360 | 0.80 | MEN1 (0.35) | MEN1KMT2ACNR2CNR1MAPT | |
| SCHEMBL14060851 | 0.79 | HPGD (0.41) | MEN1KMT2ACNR2ALDH1A1HPGD | |
| SCHEMBL16480361 | 0.79 | KDM4E (0.39) | MEN1KMT2ACNR2HPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714659-B1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | AMERICAN DYE SOURCE INC (CA) | 2017-07-05 | — | — | EP | disclosed |
| EP-2714659-B1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | AMERICAN DYE SOURCE INC (CA) | 2017-07-05 | — | — | EP | disclosed |
| US-9382259-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-9382259-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-20160016964-A1 | Compounds With Oxime Ester And/Or Acyl Groups | AMERICAN DYE SOURCE, INC. (CA) | 2016-01-21 | — | — | US | disclosed |
| US-20160016964-A1 | Compounds With Oxime Ester And/Or Acyl Groups | AMERICAN DYE SOURCE, INC. (CA) | 2016-01-21 | — | — | US | disclosed |
| US-9127017-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2015-09-08 | — | — | US | disclosed |
| US-9127017-B2 | Compounds with oxime ester and/or acyl groups | AMERICAN DYE SOURCE, INC. (CA) | 2015-09-08 | — | — | US | disclosed |
| US-20140200350-A1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | AMERICAN DYE SOURCE, INC. (CA) | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200350-A1 | COMPOUNDS WITH OXIME ESTER AND/OR ACYL GROUPS | PPOX, SCO2, LPO | MEN1 2503/4885KMT2A 324/4885CNR2 1259/4885 |
| US-20160016964-A1 | Compounds With Oxime Ester And/Or Acyl Groups | SCO2, PPOX, SQOR | MEN1 2443/4885KMT2A 277/4885CNR2 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.